Related Experiment Video
Updated: Aug 8, 2025
09:29
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
30.3K
Recent Advances in PROTAC-Based Antiviral Strategies
Haleema Ahmad1, Bushra Zia1, Hashir Husain2
1Department of Biochemistry, Faculty of Life Sciences, Aligarh Muslim University, Aligarh 202002, India.
Vaccines
|February 28, 2023
Summary
PROteolysis TArgeting Chimeras (PROTAC) technology offers a novel approach to combat viral infections by selectively degrading viral proteins. This innovative strategy holds promise for developing new antiviral therapies and vaccines.
Area of Science:
- Cell and molecular biology
- Virology
- Drug discovery
Background:
- Viral infections pose a significant global health threat, with conventional therapies proving insufficient.
- Intracellular process research has yielded innovative disease treatments.
- There is a critical need for novel antiviral therapeutic strategies.
Purpose of the Study:
- To review recent advancements in PROteolysis TArgeting Chimeras (PROTAC) technology.
- To explore the diversity and mechanism of PROTACs.
- To discuss the application of PROTACs in developing novel antiviral treatments and vaccines.
Main Methods:
- Review of current scientific literature on PROTAC technology.
- Analysis of PROTAC mechanisms for protein degradation.
- Exploration of PROTAC applications in antiviral research.
Main Results:
- PROTAC technology utilizes heterobifunctional molecules to induce targeted protein degradation.
- This technology leverages the cell's natural protein disposal machinery.
- PROTACs present a versatile platform for therapeutic intervention against viruses.
Conclusions:
- PROTAC technology represents a promising frontier for antiviral drug development.
- Targeted protein degradation via PROTACs can overcome limitations of conventional antivirals.
- Further research into PROTACs could lead to next-generation antiviral therapies and vaccines.
More Related Videos
Related Concept Videos
01:23The Antiviral System of Bacteria and Archaea: CRISPR
76
CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats is a adaptive immune system found in bacteria and archaea that protects against viral infections. This system enables prokaryotic cells to identify, remember, and neutralize foreign genetic elements, primarily bacteriophages, by storing fragments of the invader’s DNA as a genetic memory.The CRISPR immune response begins during an initial infection. Cas (CRISPR-associated) proteins play a central role in this...
76
01:10Retrovirus Life Cycles
46.4K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.4K
01:29Subviral Agents
62
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
62
02:33Retroviruses
12.6K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
12.6K